Succinobucol (AGI-1067)
(Synonyms: AGI-1067; Probucol monosuccinate) 目录号 : GC31709
A probucol derivative with diverse biological activities
Cas No.:216167-82-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Succinobucol is a metabolically stable derivative of probucol with diverse biological activities.1,2,3 It inhibits hydrogen peroxide-induced oxidation of the redox-sensitive dye H2DCF in human pulmonary artery endothelial cells (HPAECs) and U937 cells when used at concentrations of 5 and 10 ?M.1 Succinobucol (0.3-10 ?M) reduces LPS-induced production of IL-6, IL-1β, and TNF-α in peripheral blood mononuclear cells (PBMCs). It suppresses TNF-α-induced vascular cell adhesion molecule 1 (VCAM-1) promoter reporter gene expression in human aortic endothelial cells.2 Succinobucol (50 and 100 mg/kg) lowers plasma LDL levels and increases HDL levels in hypercholesterolemic cynomolgus monkeys.3 It also inhibits the formation of aortic atherosclerotic plaques in ApoE-/- or Ldlr-/- mice.
1.Kunsch, C., Luchoomun, J., Grey, J.Y., et al.Selective inhibition of endothelial and monocyte redox-sensitive genes by AGI-1067: a novel antioxidant and anti-inflammatory agentJ. Pharmacol. Exp. Ther.308(3)820-829(2004) 2.Wasserman, M.A., Sundell, C.L., Kunsch, C., et al.Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery diseaseAm. J. Cardiol.91(3A)34A-40A(2003) 3.Sundell, C.L., Somers, P.K., Meng, C.Q., et al.AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agentJ. Pharmacol. Exp. Ther.305(3)1116-1123(2003)
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.621 mL | 8.1049 mL | 16.2098 mL |
| 5 mM | 0.3242 mL | 1.621 mL | 3.242 mL |
| 10 mM | 0.1621 mL | 0.8105 mL | 1.621 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。